['non - small cell lung cancer nsclc']
['medi4736 (durvalumab)', 'vinorelbine', 'gemcitabine', 'erlotinib', 'medi4736 (durvalumab) in combination with tremelimumab (anti-ctla4)', 'tremelimumab (anti-ctla4)']

        Inclusion Criteria:

          -  Aged at least 18 years

          -  Documented evidence of NSCLC (Stage IIIB/ IV disease)

          -  Disease progression or recurrence after both a platinum-based chemotherapy regimen and
             at least 1 additional regimen for treatment of NSCLC

          -  World Health Organization (WHO) Performance Status of 0 or 1

          -  Estimated life expectancy more than 12 weeks

        Exclusion Criteria:

          -  Prior exposure to any anti-PD-1 or anti-PD-L1 antibody or anti-CTLA4

          -  Brain metastases or spinal cord compression unless asymptomatic, treated and stable
             (not requiring steroids)

          -  Active or prior documented autoimmune disease within the past 2 years

          -  Evidence of severe or uncontrolled systemic disease, including active bleeding
             diatheses or active infections including hepatitis B, C and HIV

          -  Any unresolved toxicity CTCAE (Common Terminology Criteria of Adverse Events) >Grade 2
             from previous anti-cancer therapy

          -  Known EGFR TK activating mutations or ALK rearrangements

          -  Any prior Grade ≥3 immune-related adverse event (irAE) while receiving any previous
             immunotherapy agent, or any unresolved irAE >Grade 1

          -  Active or prior documented inflammatory bowel disease (eg, Crohn's disease, ulcerative
             colitis)
      